A Phase 1 interventional study of Evolocumab in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 19th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 1, and was the 13th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 17th largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 1, and was the 13th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in aduts with normal renal function or severe renal impairment or end-stage renal disease (ESRD) receiving hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Maximum Observed Serum Concentration (Cmax) of Evolocumab
Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 800 ng/mL.
Time frame: Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab
Time frame: Predose and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Number of Participants With Adverse Events
The severity of each adverse event was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal; * life threatening (places the participant at immediate risk of death); * requires in patient hospitalization or prolongation of existing hospitalization; * results in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.
Time frame: From the first dose of study drug up until Day 57
Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes
The investigator reviewed vital signs and laboratory test results and determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.
Time frame: 57 days
Number of Participants With Anti-evolocumab Antibodies
Blood samples were tested using an electrochemiluminescence-based bridging immunoassay to detect antibodies capable of binding to evolocumab.
Time frame: 57 days
Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)
The derived log-transformed AUECday1-57 for direct LDL-C was analyzed using a mixed-effect analysis of variance model. Log-transformed baseline LDL-C was the covariate.
Time frame: 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Serum PCSK9 concentrations were determined using a qualified ELISA. The LLOQ of the assay was 15 ng/mL. Log-transformed baseline PCSK9 was included in the model as a covariate and participant as a random effect.
Time frame: Baseline and 4 hours, 2, 3, 4, 6, 8, 11, 15, 22, 29, 43, 50 and 57 days postdose
Eighteen participants were enrolled at 1 center in the United States. The first participant enrolled on 19 August 2014 and the last participant enrolled on 28 October 2014.
| Milestone | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
Serum concentrations of evolocumab were measured by a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 800 ng/mL.
| μg/mL | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Evolocumab | 21.3 ± 9.00 | 15.1 ± 8.86 | 11.7 ± 7.20 |
| day*μg/mL | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab | 185 ± 92.5 | 141 ± 109 | 102 ± 80.1 |
The severity of each adverse event was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal; * life threatening (places the participant at immediate risk of death); * requires in patient hospitalization or prolongation of existing hospitalization; * results in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. The investigator assessed whether each adverse event was possibly related to the study drug.
| participants | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Any adverse event | 1 | 1 | 2 |
| Grade ≥ 2 | 1 | 1 | 0 |
| Grade ≥ 3 | 0 | 1 | 0 |
| Grade ≥ 4 | 0 | 0 | 0 |
| Serious adverse events | 0 | 1 | 0 |
| Leading to discontinuation of study drug | 0 | 0 | 0 |
| Leading to discontinuation from study | 0 | 0 | 0 |
| Fatal adverse events | 0 | 0 | 0 |
| Treatment-related adverse events | 0 | 0 | 0 |
The investigator reviewed vital signs and laboratory test results and determined whether an abnormal value in an individual participant represented a clinically significant change from the participant's baseline values.
| participants | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes | 0 | 0 | 0 |
Blood samples were tested using an electrochemiluminescence-based bridging immunoassay to detect antibodies capable of binding to evolocumab.
| participants | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Number of Participants With Anti-evolocumab Antibodies | 0 | 0 | 0 |
The derived log-transformed AUECday1-57 for direct LDL-C was analyzed using a mixed-effect analysis of variance model. Log-transformed baseline LDL-C was the covariate.
| mg/dL*day | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C) | 4438.6 (3873.3 to 5086.5) | 4087.5 (3555.5 to 4699.1) | 4620.2 (4050.8 to 5269.6) |
Serum PCSK9 concentrations were determined using a qualified ELISA. The LLOQ of the assay was 15 ng/mL. Log-transformed baseline PCSK9 was included in the model as a covariate and participant as a random effect.
| percent change | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease |
|---|---|---|---|
| Day 1, Hour 4 | -91.69 (-94.66 to -87.09) | -79.20 (-86.63 to -67.64) | -72.95 (-82.59 to -57.97) |
| Day 2 | -96.67 (-97.86 to -94.83) | -95.87 (-97.34 to -93.57) | -94.41 (-96.40 to -91.31) |
| Day 3 | -96.67 (-97.86 to -94.83) | -96.33 (-97.64 to -94.29) | -95.58 (-97.16 to -93.14) |
| Day 4 | -96.67 (-97.86 to -94.83) | -96.33 (-97.64 to -94.29) | -96.53 (-97.77 to -94.61) |
| Day 6 | -96.67 (-97.86 to -94.83) | -96.33 (-97.64 to -94.29) | -95.39 (-97.03 to -92.83) |
| Day 8 | -96.67 (-97.86 to -94.83) | -96.33 (-97.64 to -94.29) | -95.01 (-96.79 to -92.25) |
| Day 11 | -96.67 (-97.86 to -94.83) | -95.96 (-97.40 to -93.71) | -94.69 (-96.58 to -91.75) |
| Day 15 | -90.42 (-93.84 to -85.12) | -86.41 (-91.26 to -78.86) | -82.97 (-89.04 to -73.53) |
| Day 22 | -65.84 (-78.02 to -46.40) | -57.92 (-72.95 to -34.54) | -60.33 (-74.47 to -38.36) |
| Day 29 | -49.12 (-67.26 to -20.93) | -53.66 (-70.21 to -27.91) | -51.88 (-69.03 to -25.23) |
| Day 43 | -24.93 (-51.70 to 16.67) | -36.30 (-59.05 to -0.92) | -42.44 (-62.95 to -10.56) |
| Day 50 | -2.88 (-37.51 to 50.95) | -26.57 (-52.79 to 14.22) | -37.04 (-59.48 to -2.17) |
| Day 57 | -1.46 (-36.60 to 53.14) | -14.49 (-45.03 to 33.02) | -37.74 (-59.93 to -3.25) |
Collected over From the first dose of study drug up until Day 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Evolocumab 140 mg - Normal Renal Function | — | 0/6 (0%) | 1/6 (16.7%) |
| Evolocumab 140 mg - Severe RI | — | 1/6 (16.7%) | 1/6 (16.7%) |
| Evolocumab 140 mg - ESRD Requiring Hemodialysis | — | 0/6 (0%) | 2/6 (33.3%) |
| Evolocumab 140 mg - Total | — | 1/18 (5.6%) | 4/18 (22.2%) |
| Event | Evolocumab 140 mg - Normal Renal Function | Evolocumab 140 mg - Severe RI | Evolocumab 140 mg - ESRD Requiring Hemodialysis | Evolocumab 140 mg - Total |
|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 0/6 | 1/6 | 0/6 | 1/18 |
| Event | Evolocumab 140 mg - Normal Renal Function | Evolocumab 140 mg - Severe RI | Evolocumab 140 mg - ESRD Requiring Hemodialysis | Evolocumab 140 mg - Total |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 1/18 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 1/18 |
| Tooth infectionInfections and infestations | 1/6 | 0/6 | 0/6 | 1/18 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/6 | 1/6 | 1/18 |
| Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 1/6 | 1/18 |
| DermatitisSkin and subcutaneous tissue disorders | 1/6 | 0/6 | 0/6 | 1/18 |
| Age, Continuous(years) | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease | Total |
|---|---|---|---|---|
| Mean | 51.2 ± 9.9 | 63.3 ± 7.8 | 57.0 ± 8.1 | 57.2 ± 9.6 |
| Sex: Female, Male(Participants) | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 3 | 7 |
| Male | 4 | 4 | 3 | 11 |
| Race/Ethnicity, Customized(participants) | Normal Renal Function | Severe Renal Impairment | End Stage Renal Disease | Total |
|---|---|---|---|---|
| Black (or African American) | 1 | 1 | 4 | 6 |
| White | 5 | 5 | 2 | 12 |
Ran from Aug 2014 to primary completion in Dec 2014, 4 months.
Results were first posted in Jan 2016, 1 year 1 month after primary completion.
Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 4 months is above that.
Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab